Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Apr;12(4):241-53.
doi: 10.1038/nrneph.2016.7. Epub 2016 Feb 8.

Mesenchymal stromal cells in renal transplantation: opportunities and challenges

Affiliations
Review

Mesenchymal stromal cells in renal transplantation: opportunities and challenges

Federica Casiraghi et al. Nat Rev Nephrol. 2016 Apr.

Abstract

Lifelong immunosuppressive therapy is essential to prevent allograft rejection in transplant recipients. Long-term, nonspecific immunosuppression can, however, result in life-threatening complications and fail to prevent chronic graft rejection. Bone marrow (BM)-derived multipotent mesenchymal stromal cells (MSCs) have emerged as a potential candidate for cell-based therapy to modulate the immune response in organ transplantation. These cells can repair tissue after injury and downregulate many of the effector functions of immune cells that participate in the alloimmune response, converting them into regulatory cells. The findings of preclinical and initial clinical studies support the potential tolerance-inducing effects of MSCs and highlight the unanticipated complexity of MSC therapy in kidney transplantation. In animal models of transplantation MSCs promote donor-specific tolerance through the generation of regulatory T cells and antigen-presenting cells. In some settings, however, MSCs can acquire proinflammatory properties and contribute to allograft dysfunction. The available data from small clinical studies suggest that cell infusion is safe and well tolerated by kidney transplant recipients. Ongoing and future trials will provide evidence regarding the long-term safety of MSC therapy and determine the optimum cell source (either autologous or allogeneic) and infusion protocol to achieve operational tolerance in kidney transplant recipients. These studies will also provide additional evidence regarding the risks and benefits of MSC infusion and will hopefully offer definitive answers to the important questions of when, where, how many and which types of MSCs should be infused to fully exploit their immunomodulatory, pro-tolerogenic and tissue-repairing properties.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Cell Transplant. 2006;15(8-9):711-21 - PubMed
    1. Transplant Proc. 2009 Dec;41(10):4352-6 - PubMed
    1. J Immunol. 2014 Nov 15;193(10 ):4988-99 - PubMed
    1. Curr Opin Nephrol Hypertens. 2011 Nov;20(6):610-5 - PubMed
    1. Ciba Found Symp. 1988;136:42-60 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources